Last reviewed · How we verify
Lidocaine IV
Lidocaine IV, marketed by Afyonkarahisar Health Sciences University, is an established anesthetic agent in the healthcare sector. The key composition patent for Lidocaine IV is set to expire in 2028, which currently provides a strong barrier to generic competition. The primary risk is the potential increase in market competition following the patent expiry in 2028.
At a glance
| Generic name | Lidocaine IV |
|---|---|
| Also known as | lidocaine HCl 2%, Lidocaine Hydrochloride, Lidocaine, Saline infusion once weekly for 4 successive weeks, Lidocaine infusion |
| Sponsor | Afyonkarahisar Health Sciences University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial (NA)
- Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy (PHASE4)
- The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery (PHASE4)
- Study Comparing Local/ MAC Anesthesia in Lumbar Decompression (EARLY_PHASE1)
- Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery (PHASE2)
- Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass (NA)
- Lidocaine IV Injection With Different Doses for Patients With Neuropathic Pain After Mastectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine IV CI brief — competitive landscape report
- Lidocaine IV updates RSS · CI watch RSS
- Afyonkarahisar Health Sciences University portfolio CI